Literature DB >> 12438610

Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection.

Zhi-Qiang Zhang1, Tong-Ming Fu, Danilo R Casimiro, Mary-Ellen Davies, Xiaoping Liang, William A Schleif, Larry Handt, Lynda Tussey, Minchun Chen, Aimin Tang, Keith A Wilson, Wendy L Trigona, Daniel C Freed, Charles Y Tan, Melanie Horton, Emilio A Emini, John W Shiver.   

Abstract

Expression of several major histocompatibility complex (MHC) class I alleles is associated with a protective effect against disease progression in both human immunodeficiency virus type 1 and simian immunodeficiency virus infection. To understand the mechanism underlying this effect, we investigated the expression of the MHC class I allele Mamu-A*01 in simian-human immunodeficiency virus (SHIV) infection, one of the major models for evaluation of AIDS vaccine candidates. We found that disease progression was significantly delayed in Mamu-A*01-positive rhesus monkeys infected with the highly pathogenic SHIV 89.6P. The delay corresponded not only to a noted Mamu-A*01-restricted dominant cytotoxic T-lymphocyte (CTL) response but also to a lower viral load in lymph nodes (LN) and, importantly, to minimal destruction of LN structure during early infection. In contrast, Mamu-A*01-negative monkeys exhibited massive destruction of LN structure with accompanying rapid disease progression. These data indicate that MHC class I allele-restricted CTL responses may play an important role in preservation of lymphoid tissue structure, thereby resulting in attenuation of disease progression in immunodeficiency virus infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438610      PMCID: PMC136722          DOI: 10.1128/jvi.76.24.12845-12854.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Reversibility of the pathological changes in the follicular dendritic cell network with treatment of HIV-1 infection.

Authors:  Z Q Zhang; T Schuler; W Cavert; D W Notermans; K Gebhard; K Henry; D V Havlir; H F Günthard; J K Wong; S Little; M B Feinberg; M A Polis; L K Schrager; T W Schacker; D D Richman; L Corey; S A Danner; A T Haase
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Kinetics of CD4+ T cell repopulation of lymphoid tissues after treatment of HIV-1 infection.

Authors:  Z Q Zhang; D W Notermans; G Sedgewick; W Cavert; S Wietgrefe; M Zupancic; K Gebhard; K Henry; L Boies; Z Chen; M Jenkins; R Mills; H McDade; C Goodwin; C M Schuwirth; S A Danner; A T Haase
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

3.  Rapid disease progression without seroconversion following primary human immunodeficiency virus type 1 infection--evidence for highly susceptible human hosts.

Authors:  N L Michael; A E Brown; R F Voigt; S S Frankel; J R Mascola; K S Brothers; M Louder; D L Birx; S A Cassol
Journal:  J Infect Dis       Date:  1997-06       Impact factor: 5.226

4.  Definition of five new simian immunodeficiency virus cytotoxic T-lymphocyte epitopes and their restricting major histocompatibility complex class I molecules: evidence for an influence on disease progression.

Authors:  D T Evans; P Jing; T M Allen; D H O'Connor; H Horton; J E Venham; M Piekarczyk; J Dzuris; M Dykhuzen; J Mitchen; R A Rudersdorf; C D Pauza; A Sette; R E Bontrop; R DeMars; D I Watkins
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV.

Authors:  D T Evans; L A Knapp; P Jing; J L Mitchen; M Dykhuizen; D C Montefiori; C D Pauza; D I Watkins
Journal:  Immunol Lett       Date:  1999-03       Impact factor: 3.685

6.  Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells.

Authors:  Z Zhang; T Schuler; M Zupancic; S Wietgrefe; K A Staskus; K A Reimann; T A Reinhart; M Rogan; W Cavert; C J Miller; R S Veazey; D Notermans; S Little; S A Danner; D D Richman; D Havlir; J Wong; H L Jordan; T W Schacker; P Racz; K Tenner-Racz; N L Letvin; S Wolinsky; A T Haase
Journal:  Science       Date:  1999-11-12       Impact factor: 47.728

7.  A high frequency of Mamu-A*01 in the rhesus macaque detected by polymerase chain reaction with sequence-specific primers and direct sequencing.

Authors:  L A Knapp; E Lehmann; M S Piekarczyk; J A Urvater; D I Watkins
Journal:  Tissue Antigens       Date:  1997-12

8.  HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.

Authors:  M Carrington; G W Nelson; M P Martin; T Kissner; D Vlahov; J J Goedert; R Kaslow; S Buchbinder; K Hoots; S J O'Brien
Journal:  Science       Date:  1999-03-12       Impact factor: 47.728

9.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors.

Authors:  S A Migueles; M S Sabbaghian; W L Shupert; M P Bettinotti; F M Marincola; L Martino; C W Hallahan; S M Selig; D Schwartz; J Sullivan; M Connors
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

10.  Determinants of disease in the simian immunodeficiency virus-infected rhesus macaque: characterizing animals with low antibody responses and rapid progression.

Authors:  M Dykhuizen; J L Mitchen; D C Montefiori; J Thomson; L Acker; H Lardy; C D Pauza
Journal:  J Gen Virol       Date:  1998-10       Impact factor: 3.891

View more
  58 in total

1.  Early establishment and antigen dependence of simian immunodeficiency virus-specific CD8+ T-cell defects.

Authors:  Yvonne M Mueller; Constantinos Petrovas; Duc H Do; Susan R Altork; Tracy Fischer-Smith; Jay Rappaport; John D Altman; Mark G Lewis; Peter D Katsikis
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

2.  The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication.

Authors:  Levi J Yant; Thomas C Friedrich; Randall C Johnson; Gemma E May; Nicholas J Maness; Alissa M Enz; Jeffrey D Lifson; David H O'Connor; Mary Carrington; David I Watkins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

3.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Authors:  Amitinder Kaur; Hannah B Sanford; Deirdre Garry; Sabine Lang; Sherry A Klumpp; Daisuke Watanabe; Roderick T Bronson; Jeffrey D Lifson; Margherita Rosati; George N Pavlakis; Barbara K Felber; David M Knipe; Ronald C Desrosiers
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

4.  Analysis of pigtail macaque major histocompatibility complex class I molecules presenting immunodominant simian immunodeficiency virus epitopes.

Authors:  Miranda Z Smith; C Jane Dale; Robert De Rose; Ivan Stratov; Caroline S Fernandez; Andrew G Brooks; Jason Weinfurter; Kendall Krebs; Cara Riek; David I Watkins; David H O'connor; Stephen J Kent
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.

Authors:  Philip R Johnson; Bruce C Schnepp; Mary J Connell; Daniela Rohne; Suzanne Robinson; Georgia R Krivulka; Carol I Lord; Rebekah Zinn; David C Montefiori; Norman L Letvin; K Reed Clark
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

6.  Delay of simian human immunodeficiency virus infection and control of viral replication in vaccinated macaques challenged in the presence of a topical microbicide.

Authors:  Cecilia Cheng-Mayer; Yaoxing Huang; Agegnehu Gettie; Lily Tsai; Wuze Ren; Madina Shakirzyanova; Silvana T Sina; Nataliya Trunova; James Blanchard; Lisa M Miller Jenkins; Yungtai Lo; Marco L Schito; Ettore Appella
Journal:  AIDS       Date:  2011-09-24       Impact factor: 4.177

7.  Mhc haplotype H6 is associated with sustained control of SIVmac251 infection in Mauritian cynomolgus macaques.

Authors:  Edward T Mee; Neil Berry; Claire Ham; Ulrike Sauermann; Maria T Maggiorella; Frédéric Martinon; Ernst J Verschoor; Jonathan L Heeney; Roger Le Grand; Fausto Titti; Neil Almond; Nicola J Rose
Journal:  Immunogenetics       Date:  2009-04-01       Impact factor: 2.846

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.

Authors:  Ann J Hessell; Eva G Rakasz; David M Tehrani; Michael Huber; Kimberly L Weisgrau; Gary Landucci; Donald N Forthal; Wayne C Koff; Pascal Poignard; David I Watkins; Dennis R Burton
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge.

Authors:  N A Doria-Rose; C Ohlen; P Polacino; C C Pierce; M T Hensel; L Kuller; T Mulvania; D Anderson; P D Greenberg; S-L Hu; N L Haigwood
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.